Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

By sjmartinez • June 6, 2024

Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat Commun. 2024 Jun 5;15(1):4800. doi: 10.1038/s41467-024-48995-7. Erratum for: Nat Commun. 2024 May 8;15(1):3882. doi: 10.1038/s41467-024-48073-y. PMID: 38839763; PMCID: PMC11153605.

Tags: Dermatology, DGSOM Student, Publications

Program Director Perspectives on DEI Initiatives in the Dermatology Residency Selection Process

Obed O, Rodriguez I, Lam K, Van Beek MJ, Rosenblatt A, Saavedra A, Worswick S. Program Director Perspectives on DEI Initiatives in the Dermatology Residency[...]

Construct validity of the IDEOM MSK Questionnaire (IDEOM MSK-Q): an instrument to measure musculoskeletal symptoms in patients with psoriatic disease

Perez-Chada LM, Gondo G, Grant C, Woodbury M, Kucharik AH, Armstrong AW, Eder L, Mease P, Ogdie A, Strand V, Gottlieb AB, Merola JF. Construct[...]

Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Gooderham MJ, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow H, Flack M, Korell J, Sofen H, Papp KA. Phase II Randomized Trial of[...]